查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2009073

肽類治療藥物市場規模、佔有率、趨勢和預測：按類型、製造商、合成技術、給藥途徑、應用和地區分類，2026-2034年

Peptide Therapeutics Market Size, Share, Trends and Forecast by Type, Type of Manufacturer, Synthesis Technology, Routes of Administration, Application, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 148 Pages | 商品交期: 2-3個工作天內

價格

2025年全球胜肽類藥物市場規模為497億美元。展望未來，IMARC Group預測，該市場將在2026年至2034年間以6.95%的複合年成長率成長，到2034年達到926億美元。目前，北美市場主導地位，預計2025年將佔據約40.9%的市場。推動該市場成長的主要因素是癌症、代謝性疾病和感染疾病的日益普遍，導致對標靶高效治療方法的需求不斷成長。胜肽合成技術、藥物傳遞系統以及生物利用度的提高正在加速胜肽類藥物的研究和商業性化應用。此外，監管部門的積極核准、生物製藥領域投資的增加以及個人化醫療應用的持續拓展也是推動胜肽類藥物市場佔有率成長的關鍵因素。

肽類藥物研發領域的持續進步，例如人工智慧（AI）和計算建模的整合，使得快速識別具有更高療效的生物活性序列成為可能，從而推動了該市場的發展。此外，針對代謝性疾病和感染疾病的臨床試驗項目不斷拓展，也進一步刺激了市場需求。同時，對生產能力的投資增加，包括固相胜肽合成（SPPS）和混合合成方法，正在推動成本效益更高的規模化生產，並刺激市場成長。例如，2025年4月3日，CordenPharma宣布了一項超過10億歐元（約11億美元）的策略投資，用於擴大其全球胜肽類藥物生產能力​​。該公司的成長策略包括新增2.6萬平方公尺的生產空間，並將其固相胜肽合成（SPPS）產能擴大3萬公升。此外，生物技術Start-Ups與大型製藥企業之間的策略合作也正在支持加速創新和商業化進程。

在美國，由於政府針對罕見疾病治療的專項舉措，市場正蓬勃發展。根據產業報告顯示，美國食品藥物管理局(FDA) 為部分臨床試驗提供資金支持，以促進罕見疾病藥物的研發。 2024 年 10 月，FDA 宣布將在四年內撥款 1,720 萬美元，用於七項新的臨床研究，其中包括一項 III 期臨床試驗（2024 財政年度）。這項公共投資正在加強早期研發活動，並為基於胜肽的治療方法在罕見疾病和複雜疾病治療領域的發展創造更有利的環境。此外，個人化醫療的日益普及也推動了對基於胜肽的精準治療方法的需求。同時，專注於胜肽領域的合約研究組織 (CRO) 和合約開發與受託製造廠商(CDMO) 的蓬勃發展，也使企業能夠有效率地從臨床前研究過渡到商業化。最後，人們對微創給藥方式的日益關注，也推動了注射劑和經皮肽製劑的研發。此外，FDA提供的支持性監管途徑，例如對胜肽類候選藥物的快速通道和突破性療法認定，正在進一步加速其進入市場。

肽類治療藥物市場的發展趨勢：

慢性病盛行率增加

癌症、糖尿病和心血管疾病等慢性病盛行率的不斷上升是推動市場發展的主要因素。根據美國國家生物技術資訊中心（NCBI）預測，全球癌症患者人數將顯著增加，到2050年將達到3530萬，比2022年預計的2000萬患者成長76.6%。肽類藥物以其高特異性和靶向特定生物過程的能力而聞名，為需要長期有效管理的慢性病提供了一種極具前景的治療選擇。此外，文明病的增加和全球人口老化也推動了對創新標靶治療方法的需求。肽類療法能夠滿足這些需求，因為它們具有獨特的作用機制，與傳統小分子藥物相比，副作用更小。此外，政府和製藥業對研發的投入正在加速新型胜肽類藥物的開發，並拓展治療的可能性。同時，胜肽類藥物合成、製劑和遞送技術的進步正在提高其生物利用度和穩定性，從而對市場產生積極影響。因此，肽類藥物市場透過滿足慢性病管理方面尚未滿足的重大需求，正在經歷強勁成長。

胜肽合成和遞送技術的進展

胜肽合成和藥物傳遞技術的持續進步極大地促進了肽類療法的研發和療效提升。固相肽合成（SPPS）和自動化合成平台等創新技術正在簡化高品質胜肽的生產流程，使其更有效率且經濟。此外，奈米顆粒製劑和經皮吸收貼片改進的遞送系統正在解決胜肽的穩定性和生物利用度方面的挑戰，有望提振胜肽類療法市場前景。這些技術創新不僅增強了胜肽的治療潛力，也拓展了其在腫瘤學、內分泌學和免疫學等多個醫學領域的應用。根據一份行業報告顯示，2023年至2024年間，ClinicalTrials.gov網站上註冊了近200項使用胜肽疫苗治療感染疾病、癌症和進行相關治療的臨床試驗。隨著這些技術的不斷發展，預計將透過支持新型高效肽類治療方法的研發，推動市場成長。

人們越來越關注個人化醫療

全球市場對個人化醫療日益成長的興趣是推動市場成長要素。對肽類藥物市場的分析表明，肽類藥物市場正因個人化醫療而擴張。個人化醫療根據遺傳、環境和生活方式因素為每位患者定製藥物。肽類藥物尤其適合這種方法，因為它們可以被設計成針對特定路徑或個別患者特有的生物標記。基因組學和生物標記研究的進展使得識別可能受益於胜肽類治療方法的患者群體變得更加容易。隨著醫療保健系統日益認知到個人化治療在改善患者預後和最大限度減少副作用方面的價值，對肽類藥物的需求預計將會增加。這種向個人化醫療的轉變正在塑造製藥業的未來前景。據美國食品藥物管理局（FDA）稱，自2014年以來，超過25%的新核准藥物已用於個人化治療。一份行業報告強調，採用個人化治療方案，85%的高血壓患者和80%的2型糖尿病患者達到了預期的臨床療效，而採用標準治療方案的患者中只有65%達到了這一目標。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球胜肽類治療市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依類型

  • 創新的
  • 非專利的

第7章 市場區隔：依製造商類型分類

  • 外包
  • 內部生產

第8章 市場區隔：依合成技術分類

  • 固相胜肽合成
  • 液相胜肽合成
  • 混合技術

第9章 市場區隔：依給藥途徑

  • 腸外
  • 口服
  • 其他

第10章 市場區隔：依應用領域分類

  • 消化系統疾病
  • 神經系統疾病
  • 代謝性疾病
  • 癌症
  • 其他

第11章 市場區隔：按地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第12章 SWOT 分析

第13章：價值鏈分析

第14章：波特五力分析

第15章：價格分析

第16章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Amgen Inc.
    • Apitope International NV
    • Arch Biopartners Inc.
    • AstraZeneca plc
    • Circle Pharma Inc.
    • Corden Pharma GmbH
    • F. Hoffmann-La Roche AG
    • Ipsen Group
    • Lonza Group AG
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Teva Pharmaceuticals Industries Ltd.
    • Zealand Pharma A/S
Product Code: SR112026A4510

The global peptide therapeutics market size was valued at USD 49.7 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 92.6 Billion by 2034, exhibiting a CAGR of 6.95% during 2026-2034. North America currently dominates the market, holding a significant market share of around 40.9% in 2025 . The market is driven by the growing prevalence of cancer, metabolic disorders, and infectious diseases, prompting increased demand for targeted and efficient treatments. Advancements in peptide synthesis technologies, drug delivery systems, and bioavailability enhancements are accelerating research and commercial adoption. Additionally, favorable regulatory approvals, rising investments in biopharmaceutical, and expanding applications in personalized medicine are key factors augmenting the peptide therapeutic market share.

The market is driven by continual advancements, including the integration of artificial intelligence (AI) and computational modeling in peptide drug discovery, enabling faster identification of bioactive sequences with improved efficacy. Additionally, expanding clinical trial pipelines for metabolic and infectious diseases further reinforces demand. Besides this, growing investments in manufacturing capabilities, including solid-phase peptide synthesis (SPPS) and hybrid synthesis methods, are facilitating cost-effective scale-up and providing an impetus to the market. For instance, on April 3, 2025, CordenPharma announced a strategic investment of more than EUR 1 Billion (about USD 1.1 Billion) to expand its global peptide production capacity. The company's growth ambitions include adding 26,000 square meters of manufacturing space and 30,000 L of solid-phase peptide synthesis (SPPS) capability. Moreover, strategic partnerships between biotech startups and large pharmaceutical firms are supporting accelerated innovation and commercialization.

In the United States, the market is gaining momentum through targeted government initiatives aimed at rare disease treatment. According to industry reports, the U.S. FDA provides financial support for a select number of clinical trials to aid sponsors in developing medicinal products for rare conditions. In October 2024, the FDA announced funding for seven new clinical studies in fiscal year 2024, including one Phase 3 trial, with a total allocation of USD 17.2 Million over four years. This public sector investment enhances early-stage research and development activities, contributing to a more favorable environment for the advancement of peptide-based therapies addressing rare and complex diseases. Furthermore, the increasing prevalence of personalized medicine is also fueling the need for peptide-based precision therapies. In addition to this, the robust presence of CROs and CDMOs with specialized peptide capabilities allows companies to progress from preclinical to commercial stages efficiently. Also, rising interest in minimally invasive drug delivery has driven the development of injectable and transdermal peptide formulations. Apart from this, supportive FDA regulatory pathways, including fast-track and breakthrough therapy designations for peptide candidates, have further accelerated market entry.

PEPTIDE THERAPEUTICS MARKET TRENDS:

Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular conditions, is a primary factor providing an impetus to the market. According to the NCBI, global cancer cases are projected to rise significantly, reaching 35.3 million by 2050, representing a 76.6% increase over the expected 20 million cases in 2022. Peptides, known for their high specificity and ability to target precise biological processes, offer promising treatment options for chronic diseases, which often require long-term and effective management solutions. In line with this, with a rise in lifestyle-related health conditions and an aging global population, the demand for innovative, targeted therapies is on the rise. Peptide therapeutics align well with this need due to their unique mechanisms of action, which minimize side effects as compared to traditional small-molecule drugs. Moreover, government and pharmaceutical sector investments in research and development (R&D) drive the creation of novel peptides, expanding treatment possibilities. In addition to this, advancements in peptide synthesis, formulation, and delivery have enhanced their bioavailability and stability, which is positively impacting the market, Consequently, there is a robust peptide therapeutics market growth, addressing critical unmet needs in chronic disease management.

Advancements in Peptide Synthesis and Delivery Technologies

Continual advancements in peptide synthesis and drug delivery technologies are significantly supporting the development and efficacy of peptide therapeutics. Innovative techniques, such as solid-phase peptide synthesis (SPPS) and automated synthesis platforms, have streamlined the production of high-quality peptides, making them more efficient and cost-effective. Moreover, improved delivery systems, such as nanoparticle formulations and transdermal patches, are addressing challenges related to peptide stability and bioavailability, which is expected to create a positive peptide therapeutics market outlook. In addition to this, these technological innovations not only enhance the therapeutic potential of peptides but also expand their applications across various medical fields, including oncology, endocrinology, and immunology. According to an industry report, nearly 200 clinical trials employing peptide vaccines for infectious diseases, cancer prevention, and therapy were documented on ClinicalTrials.gov between 2023 and 2024. As these advancements continue to evolve, they are expected to propel the market by supporting the development of novel and effective peptide-based therapies.

Growing Focus on Personalized Medicine

The increasing emphasis on personalized medicine is acting as another major growth-inducing factor in the market across the globe. According to the peptide therapeutics market analysis, the market for peptide therapies is growing due to personalized medicine, which customizes medicines to patients based on genetic, environmental, and lifestyle factors. Peptides are particularly well-suited for this approach, as they can be designed to target specific pathways and biological markers unique to individual patients. The rise of genomics and biomarker research is facilitating the identification of patient populations that may benefit from peptide-based therapies. As healthcare systems increasingly recognize the value of personalized treatments in improving patient outcomes and minimizing side effects, the need for peptide therapeutics is expected to rise. This shift toward personalized medicine is shaping the future landscape of the pharmaceutical industry. Over 25% of all new drug approvals since 2014 have been used for personalized treatments, according to the FDA. An industry report highlights that 85% of hypertension patients and 80% of type 2 diabetes patients reached target clinical outcomes with personalized approaches, compared to 65% under standard treatments.

PEPTIDE THERAPEUTICS INDUSTRY SEGMENTATION:

Analysis by Type:

  • Innovative
  • Generic

Innovative leads the market with around 64.0% of market share in 2025. These therapeutics are typically first-in-class or best-in-class drugs, characterized by novel mechanisms of action, enhanced targeting abilities, and improved pharmacokinetic profiles. Unlike generic or biosimilar peptides, innovative peptides are developed through advanced technologies such as solid-phase peptide synthesis, recombinant DNA methods, and peptide conjugation platforms. Their importance is underscored by their high therapeutic value across complex diseases, including cancer, metabolic disorders, and rare genetic conditions. Apart from this, pharmaceutical companies are extensively investing in research and development (R&D) for innovative peptides due to their potential for exclusivity and premium pricing. Furthermore, regulatory incentives like orphan drug designations and fast-track approvals have boosted their commercial viability. As the demand for precision medicine and biologically targeted therapies grows, the innovative segment remains a cornerstone for shaping the future trajectory of peptide drug development and commercialization.

Analysis by Type of Manufacturer:

  • Outsourced
  • In-house

In-house leads the market with around 64.4% of market share in 2025. In-house manufacturing offers pharmaceutical companies' greater control over production quality, timelines, and intellectual property. By maintaining internal capabilities, companies can ensure consistency in complex synthesis processes, particularly crucial for high-purity peptide drugs that require stringent quality standards. In-house facilities allow for tighter integration between research and development (R&D) and manufacturing, enabling faster transitions from clinical development to commercial production. This also enhances flexibility in scaling production based on demand and allows quicker implementation of process improvements or modifications. For companies developing innovative or proprietary peptides, in-house manufacturing safeguards sensitive formulations and reduces reliance on external partners. It also helps in managing regulatory compliance more effectively, especially for therapies targeting rare diseases or requiring specialized delivery methods. As peptide drugs become more complex and personalized, the role of in-house manufacturing is expected to expand in the market.

Analysis by Synthesis Technology :

  • Solid Phase Peptide Synthesis
  • Liquid Phase Peptide Synthesis
  • Hybrid Technology

Liquid phase peptide synthesis leads the market with around 44.3% of market share in 2025. It is an important technology to produce simple peptides at a large scale. This method, which involves synthesizing peptides in solution using soluble reactants, offers advantages such as better reaction monitoring, easier purification of intermediates, and cost-effectiveness for high-volume manufacturing. LPPS is especially useful when producing peptides that do not require complex modifications or sequences, making it a practical choice for established, off-patent therapeutic peptides or early-stage development. Despite the broader industry shift toward solid phase peptide synthesis (SPPS) for complex molecules, LPPS continues to be relevant due to its scalability, efficiency in batch processing, and lower reagent cost. Manufacturers with expertise in LPPS achieve high yields with consistent purity, which is critical for meeting regulatory standards. Its continued application reinforces its role as a foundational technology in the peptide production landscape.

Analysis by Routes of Administration :

  • Parenteral
  • Oral
  • Others

Parental leads the market with around 88.7% of market share in 2025. Administering peptides via injection, typically intravenous, subcutaneous, or intramuscular, ensures rapid absorption, controlled dosing, and optimal therapeutic concentration in the bloodstream. This route bypasses enzymatic degradation and first-pass metabolism, which are major limitations for oral formulations. In the market, parenteral delivery supports a wide range of treatments, including hormone regulation, cancer therapy, metabolic disorders, and rare disease management. Many blockbuster peptide drugs, such as insulin analogs and GLP-1 receptor agonists, rely on subcutaneous administration for long-term disease control. Advances in delivery devices, including auto-injectors and pre-filled syringes, have also improved patient compliance and convenience. As research continues into alternative delivery methods, parenteral administration remains the standard for ensuring therapeutic efficacy and safety of peptide-based treatments.

Analysis by Application :

  • Gastrointestinal Disorders
  • Neurological Disorders
  • Metabolic Disorders
  • Cancer
  • Others

Metabolic disorders lead the market with around 27.9% of market share in 2025 due to the rising global incidence of conditions like diabetes, obesity, and metabolic syndrome. Peptide-based drugs offer distinct advantages, such as high specificity, low toxicity, and the ability to modulate complex biological pathways, making them ideal for treating these disorders. One of the most notable examples is the widespread use of GLP-1 receptor agonists like semaglutide and liraglutide in managing type 2 diabetes and obesity. The demand for such treatments is accelerating as lifestyle-related metabolic diseases become more prevalent across both developed and emerging economies. Additionally, advancements in peptide synthesis and drug delivery systems are expanding the therapeutic potential of peptides, enhancing their stability and bioavailability. This has encouraged pharmaceutical companies to invest heavily in research and development (R&D) for peptide drugs targeting metabolic pathways, driving innovation and growth in this segment of market.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of over 40.9% driven by a strong pharmaceutical industry, advanced healthcare infrastructure, and high research and development (R&D) investment. The region, particularly the United States, hosts a concentration of major biotech firms and research institutions actively developing peptide-based drugs for cancer, metabolic disorders, and rare diseases. Regulatory support from agencies like the FDA, along with streamlined approval pathways for orphan drugs and breakthrough therapies, has accelerated market entry for innovative peptides. Additionally, the region benefits from a high prevalence of chronic diseases, growing demand for personalized medicine, and favorable reimbursement structures that support the adoption of advanced therapies. The region also sees active collaborations between academic centers and pharmaceutical companies, encouraging continuous innovation in peptide drug development. With a strong clinical trial ecosystem and rising patient awareness, North America remains a key contributor to both the revenue and innovation pipeline of the global market.

KEY REGIONAL TAKEAWAYS:

UNITED STATES PEPTIDE THERAPEUTICS MARKET ANALYSIS

In 2025, the United States holds a substantial share of around 86.50% of the market share in North America. The market in the United States is primarily driven by increased research and development (R&D) investments by pharmaceutical and biotechnology companies. In line with this, the heightened presence of advanced healthcare infrastructure and supportive reimbursement frameworks is accelerating the clinical adoption of peptide-based therapies. The rising incidence of chronic illnesses, including metabolic and cardiovascular disorders, requiring precise and targeted treatment solutions, is supporting market demand. According to the American Heart Association's 2025 statistical report, the United States recorded 941,652 cardiovascular disease (CVD)-related deaths in 2022, marking an increase of over 10,000 deaths from the 931,578 reported in 2021. Furthermore, growing public and private funding for rare disease therapeutics, encouraging peptide-centric pipelines, is propelling growth in the market. The rapid integration of artificial intelligence and machine learning into drug discovery processes, enabling rapid identification of therapeutic peptide candidates, is contributing to industry innovation and market appeal. Similarly, numerous collaborations between academic institutions and industry players that augment translational research and commercialization prospects are strengthening market presence. Additionally, increased reliance on contract manufacturing organizations for scalable peptide production is optimizing supply chains and bolstering product sales.

EUROPE PEPTIDE THERAPEUTICS MARKET ANALYSIS

The European market is experiencing growth due to strong regulatory incentives for orphan and specialty drugs, which are promoting innovation in peptide-based treatments. In accordance with this, increased funding through Horizon Europe and national research initiatives is accelerating the clinical development of peptide formulations. Similarly, the rising burden of age-related conditions, including osteoporosis and neurodegenerative diseases, is increasing the peptide therapeutics market demand. According to NCBI, the annual number of osteoporotic fractures in the European Union was estimated at 4.28 million in 2019 and is projected to rise to 5.34 million by 2034, indicating a significant increase in fracture-related healthcare needs across the region. The growing manufacturing footprint in countries such as Germany and Switzerland, enhancing production efficiency, is supporting market scalability. Furthermore, the rising number of EMA approvals for novel peptide drugs, improving accessibility and clinical adoption, is bolstering market reach. The rapid integration of peptide-based solutions into antimicrobial resistance (AMR) strategies aligned with EU health goals is further strengthening market demand. Besides this, robust academic research in peptide chemistry and translational science, fostering innovation pipelines, is expanding therapeutic potential in the market.

ASIA PACIFIC PEPTIDE THERAPEUTICS MARKET ANALYSIS

The market in the Asia Pacific is gaining momentum due to rising healthcare expenditure across emerging economies, improving access to specialized treatments. In addition to this, the increasing prevalence of lifestyle-related disorders, such as diabetes and obesity, requires targeted therapeutic approaches, which are also driving product demand. As per an industry report, India leads globally with 212 million people living with diabetes, surpassing China's 148 million. Also, India has the highest number of individuals over the age of 30 with untreated diabetes, estimated at 133 million, compared to 78 million in China. Similarly, the rapid scale-up of domestic pharmaceutical manufacturing in countries like India, China, and South Korea, enabling cost-efficient peptide production, is enhancing market competitiveness. Moreover, the ongoing establishment of regional research and development (R&D) centers by global pharmaceutical firms supporting innovation and technology exchange is strengthening the market landscape. Apart from this, growing public awareness of personalized medicine and preventive care, particularly in the urban population, is accelerating the product uptake across a range of treatment areas.

LATIN AMERICA PEPTIDE THERAPEUTICS MARKET ANALYSIS

In Latin America, the market is progressing, attributed to the increasing burden of chronic diseases such as diabetes and cardiovascular disorders. Similarly, significant improvements in regional healthcare systems, enhancing access to specialty therapies, are supporting the broader adoption of peptide-based drugs. The Federal Government of Brazil increased the Ministry of Health's budget for specialized treatments by 34% between 2022 and 2024, raising the allocation from BRL 54.9 Billion in 2022 (about USD 10.98 Billion) to BRL 74.7 Billion (about USD 14.94 Billion) in 2024. Furthermore, various collaborations between domestic pharmaceutical firms and global players, facilitating technology transfer and localized production, are strengthening market infrastructure. Moreover, active participation in international regulatory alignment efforts, reducing barriers to entry for innovative therapies, is streamlining approval processes and accelerating market expansion across the region.

MIDDLE EAST AND AFRICA PEPTIDE THERAPEUTICS MARKET ANALYSIS

In the Middle East and Africa, the market is advancing, supported by the growing incidences of lifestyle-related diseases such as obesity and type 2 diabetes, particularly in urban centers. According to the World Obesity Federation, the number of obese adults in the Middle East and Africa is projected to increase by over 200%, rising from 11.8 million to 37.2 million by 2030. Additionally, a rise in government-led healthcare reforms and increased public investment in specialty medical services are improving access to advanced treatments in the market. The strategic expansion of pharmaceutical distribution networks across the Gulf and Sub-Saharan regions is enhancing product availability. Moreover, growing participation in international clinical research collaborations is fostering innovation and promoting the integration of peptide-based therapies into national treatment protocols.

COMPETITIVE LANDSCAPE:

The market is characterized by intense competition driven by technological advancements, growing demand for targeted treatments, and expanding therapeutic applications. Several players are focusing on innovative drug delivery methods, including oral, transdermal, and nanoparticle-based systems, to overcome challenges such as enzymatic degradation and short half-life. Biosynthetic techniques and solid-phase peptide synthesis are refined for scalability and cost efficiency. According to the peptide therapeutics market forecast, the sector is expected to grow steadily in the future years, driven by increased research and development (R&D) spending and favorable regulatory environments for biologics. Peptides have promising clinical applications in oncology, endocrinology, and infectious disorders. Market participants are also engaging in strategic collaborations, licensing deals, and contract manufacturing partnerships to strengthen their portfolios. The market landscape is further shaped by patent expiries, prompting an influx of generics and biosimilars. The emphasis is shifting toward long-acting and multifunctional peptides, reflecting the push for improved patient outcomes and competitive differentiation.

The report provides a comprehensive analysis of the competitive landscape in the peptide therapeutics market with detailed profiles of all major companies, including:

  • Amgen Inc.
  • Apitope International NV
  • Arch Biopartners Inc.
  • AstraZeneca plc
  • Circle Pharma Inc.
  • Corden Pharma GmbH
  • F. Hoffmann-La Roche AG
  • Ipsen Group
  • Lonza Group AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Zealand Pharma A/S

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the peptide therapeutics market?

2. What is the future outlook of the peptide therapeutics market?

3. What are the key factors driving the peptide therapeutics market?

4. Which region accounts for the largest peptide therapeutics market?

5. Which are the leading companies in the global peptide therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Peptide Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Innovative
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Generic
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Type of Manufacturer

  • 7.1 Outsourced
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 In-house
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Synthesis Technology

  • 8.1 Solid Phase Peptide Synthesis
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Liquid Phase Peptide Synthesis
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Hybrid Technology
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Routes of Administration

  • 9.1 Parenteral
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Oral
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Application

  • 10.1 Gastrointestinal Disorders
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Neurological Disorders
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Metabolic Disorders
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Cancer
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Others
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Amgen Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Apitope International NV
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
    • 16.3.3 Arch Biopartners Inc.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
    • 16.3.4 AstraZeneca plc
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 Circle Pharma Inc.
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
    • 16.3.6 Corden Pharma GmbH
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
    • 16.3.7 F. Hoffmann-La Roche AG
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 SWOT Analysis
    • 16.3.8 Ipsen Group
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 Lonza Group AG
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Novo Nordisk A/S
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11 Pfizer Inc.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis
    • 16.3.12 Teva Pharmaceuticals Industries Ltd.
      • 16.3.12.1 Company Overview
      • 16.3.12.2 Product Portfolio
      • 16.3.12.3 Financials
      • 16.3.12.4 SWOT Analysis
    • 16.3.13 Zealand Pharma A/S
      • 16.3.13.1 Company Overview
      • 16.3.13.2 Product Portfolio
      • 16.3.13.3 Financials

List of Figures

  • Figure 1: Global: Peptide Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Peptide Therapeutics Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Peptide Therapeutics Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Peptide Therapeutics Market: Breakup by Type (in %), 2025
  • Figure 5: Global: Peptide Therapeutics Market: Breakup by Type of Manufacturer (in %), 2025
  • Figure 6: Global: Peptide Therapeutics Market: Breakup by Synthesis Technology (in %), 2025
  • Figure 7: Global: Peptide Therapeutics Market: Breakup by Routes of Administration (in %), 2025
  • Figure 8: Global: Peptide Therapeutics Market: Breakup by Application (in %), 2025
  • Figure 9: Global: Peptide Therapeutics Market: Breakup by Region (in %), 2025
  • Figure 10: Global: Peptide Therapeutics (Innovative) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Peptide Therapeutics (Innovative) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Peptide Therapeutics (Generic) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Peptide Therapeutics (Generic) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Peptide Therapeutics (Outsourced) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Peptide Therapeutics (Outsourced) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Peptide Therapeutics (In-house) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Peptide Therapeutics (In-house) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Peptide Therapeutics (Solid Phase Peptide Synthesis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Peptide Therapeutics (Solid Phase Peptide Synthesis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Peptide Therapeutics (Liquid Phase Peptide Synthesis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Peptide Therapeutics (Liquid Phase Peptide Synthesis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Peptide Therapeutics (Hybrid Technology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Peptide Therapeutics (Hybrid Technology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Peptide Therapeutics (Parenteral) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Peptide Therapeutics (Parenteral) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Peptide Therapeutics (Oral) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Peptide Therapeutics (Oral) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Peptide Therapeutics (Other Routes of Administration) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Peptide Therapeutics (Other Routes of Administration) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Peptide Therapeutics (Gastrointestinal Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Peptide Therapeutics (Gastrointestinal Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Peptide Therapeutics (Neurological Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Peptide Therapeutics (Neurological Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Peptide Therapeutics (Metabolic Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Peptide Therapeutics (Metabolic Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Global: Peptide Therapeutics (Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Global: Peptide Therapeutics (Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Global: Peptide Therapeutics (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Global: Peptide Therapeutics (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: North America: Peptide Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: North America: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: United States: Peptide Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: United States: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Canada: Peptide Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Canada: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Asia-Pacific: Peptide Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Asia-Pacific: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: China: Peptide Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: China: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Japan: Peptide Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Japan: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: India: Peptide Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: India: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: South Korea: Peptide Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: South Korea: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Australia: Peptide Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Australia: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Indonesia: Peptide Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Indonesia: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Others: Peptide Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Others: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Europe: Peptide Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Europe: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Germany: Peptide Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Germany: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: France: Peptide Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: France: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: United Kingdom: Peptide Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: United Kingdom: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Italy: Peptide Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Italy: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Spain: Peptide Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Spain: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Russia: Peptide Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Russia: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Others: Peptide Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Others: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Latin America: Peptide Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Latin America: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Brazil: Peptide Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Brazil: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Mexico: Peptide Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Mexico: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Others: Peptide Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 85: Others: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Middle East and Africa: Peptide Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 87: Middle East and Africa: Peptide Therapeutics Market: Breakup by Country (in %), 2025
  • Figure 88: Middle East and Africa: Peptide Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 89: Global: Peptide Therapeutics Industry: SWOT Analysis
  • Figure 90: Global: Peptide Therapeutics Industry: Value Chain Analysis
  • Figure 91: Global: Peptide Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Peptide Therapeutics Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Peptide Therapeutics Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 3: Global: Peptide Therapeutics Market Forecast: Breakup by Type of Manufacturer (in Million USD), 2026-2034
  • Table 4: Global: Peptide Therapeutics Market Forecast: Breakup by Synthesis Technology (in Million USD), 2026-2034
  • Table 5: Global: Peptide Therapeutics Market Forecast: Breakup by Routes of Administration (in Million USD), 2026-2034
  • Table 6: Global: Peptide Therapeutics Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 7: Global: Peptide Therapeutics Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 8: Global: Peptide Therapeutics Market: Competitive Structure
  • Table 9: Global: Peptide Therapeutics Market: Key Players